India Pharma Q1 Preview: Home Gains But Subdued US Growth
Executive Summary
Leading Indian firms are expected to report revenue growth, propped by a strained domestic business in the first quarter of the last fiscal year. But it is management commentary around pricing developments in the US, a key revenue contributor for most frontline firms, and plans around specialty product introductions that are expected to be keenly tracked by investors.